Exact Sciences announced the launch of Oncodetect — a new test designed to detect molecular residual disease (MRD) across multiple solid tumors.
The Oncodetect test delivers "Detected” or “Not Detected” results, accompanied by quantitative data to help support adjuvant therapy decisions, evaluate treatment response, and monitor cancer recurrence. The test tracks up to 200 tumor-specific variants and identifies even trace amounts of ctDNA — down to 1 ctDNA molecule in 20,000 cfDNA molecules. This sensitivity enables earlier detection of CRC recurrence compared to imaging alone, the company said.
"After surgery and definitive therapy, such as chemotherapy or radiation, the risk for cancer recurrence remains a major concern. Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care," said Brian Baranick, Executive Vice President and General Manager, Precision Oncology at Exact Sciences.
Exact Sciences said it is working with Medicare to secure reimbursement for the test, ensuring broad patient access nationwide. The company is also advancing clinical and analytical validation studies across multiple solid tumors, supported by strategic partnerships for multi-cancer evidence generation.
The Oncodetect test builds on 20 years of genomic testing experience established by the Oncotype DX Breast Recurrence Score test. Integrated into a digital experience, supported by the ExactNexus technology platform, the Oncodetect test can be ordered with other Exact Sciences tests, including OncoExTra (comprehensive genomic profiling) and Riskguard (hereditary cancer testing).
